Subclinical myocardial injury in patients with Facioscapulohumeral muscular dystrophy 1 and preserved ejection fraction - assessment by cardiovascular magnetic resonance.
Adult
Arrhythmias, Cardiac
/ etiology
Asymptomatic Diseases
Cardiomyopathies
/ diagnostic imaging
Case-Control Studies
Cross-Sectional Studies
Female
Fibrosis
Humans
Magnetic Resonance Imaging, Cine
Male
Middle Aged
Muscular Dystrophy, Facioscapulohumeral
/ complications
Myocardium
/ pathology
Predictive Value of Tests
Prognosis
Prospective Studies
Stroke Volume
Systole
Ventricular Function, Left
FSHD
Fat
Fibrosis
Magnetic resonance imaging
Sex & gender
Journal
Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
ISSN: 1532-429X
Titre abrégé: J Cardiovasc Magn Reson
Pays: England
ID NLM: 9815616
Informations de publication
Date de publication:
29 04 2019
29 04 2019
Historique:
received:
08
07
2018
accepted:
02
04
2019
entrez:
30
4
2019
pubmed:
30
4
2019
medline:
29
1
2020
Statut:
epublish
Résumé
Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is an autosomal dominant and the third most common inherited muscle disease. Cardiac involvement is currently described in several muscular dystrophies (MD), but there are conflicting reports in FSHD1. Mostly, FSHD1 is recognized as MD with infrequent cardiac involvement, but sudden cardiac deaths are reported in single cases. The aim of this study is to investigate whether subclinical cardiac involvement in FSHD1 patients is detectable in preserved left ventricular systolic function applying cardiovascular magnetic resonance (CMR). We prospectively included patients with genetically confirmed FSHD1 (n = 52, 48 ± 15 years) and compared them with 29 healthy age-matched controls using a 1.5 T CMR scanner. Myocardial tissue differentiation was performed qualitatively using focal fibrosis imaging (late gadolinium enhancement (LGE)), fat imaging (multi-echo sequence for fat/water-separation) and parametric T2- and T1-mapping for quantifying inflammation and diffuse fibrosis. Extracellular volume fraction was calculated. A 12-lead electrocardiogram and 24-h Holter were performed for the assessment of MD-specific Groh-criteria and arrhythmia. Focal fibrosis by LGE was present in 13 patients (25%,10 men), fat infiltration in 7 patients (13%,5 men). T2 values did not differ between FSHD1 and healthy controls. Native T1 mapping revealed significantly higher values in patients (global native myocardial T1 values basal: FSHD1: 1012 ± 26 ms vs. controls: 985 ± 28 ms, p < 0.01, medial FSHD1: 994 ± 37 ms vs. controls: 982 ± 28 ms, p = 0.028). This was also evident in regions adjacent to focal fibrosis, indicating diffuse fibrosis. Groh-criteria were positive in 1 patient. In Holter, arrhythmic events were recorded in 10/43 subjects (23%). Patients with FSHD1 and preserved left ventricular ejection fraction present focal and diffuse myocardial injury. Longitudinal multi-center trials are needed to define the impact of myocardial changes as well as a relation between myocardial injury and arrhythmias on long-term prognosis and therapeutic decision-making. ISRCTN registry with study ID ISRCTN13744381 .
Sections du résumé
BACKGROUND
Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is an autosomal dominant and the third most common inherited muscle disease. Cardiac involvement is currently described in several muscular dystrophies (MD), but there are conflicting reports in FSHD1. Mostly, FSHD1 is recognized as MD with infrequent cardiac involvement, but sudden cardiac deaths are reported in single cases. The aim of this study is to investigate whether subclinical cardiac involvement in FSHD1 patients is detectable in preserved left ventricular systolic function applying cardiovascular magnetic resonance (CMR).
METHODS
We prospectively included patients with genetically confirmed FSHD1 (n = 52, 48 ± 15 years) and compared them with 29 healthy age-matched controls using a 1.5 T CMR scanner. Myocardial tissue differentiation was performed qualitatively using focal fibrosis imaging (late gadolinium enhancement (LGE)), fat imaging (multi-echo sequence for fat/water-separation) and parametric T2- and T1-mapping for quantifying inflammation and diffuse fibrosis. Extracellular volume fraction was calculated. A 12-lead electrocardiogram and 24-h Holter were performed for the assessment of MD-specific Groh-criteria and arrhythmia.
RESULTS
Focal fibrosis by LGE was present in 13 patients (25%,10 men), fat infiltration in 7 patients (13%,5 men). T2 values did not differ between FSHD1 and healthy controls. Native T1 mapping revealed significantly higher values in patients (global native myocardial T1 values basal: FSHD1: 1012 ± 26 ms vs. controls: 985 ± 28 ms, p < 0.01, medial FSHD1: 994 ± 37 ms vs. controls: 982 ± 28 ms, p = 0.028). This was also evident in regions adjacent to focal fibrosis, indicating diffuse fibrosis. Groh-criteria were positive in 1 patient. In Holter, arrhythmic events were recorded in 10/43 subjects (23%).
CONCLUSIONS
Patients with FSHD1 and preserved left ventricular ejection fraction present focal and diffuse myocardial injury. Longitudinal multi-center trials are needed to define the impact of myocardial changes as well as a relation between myocardial injury and arrhythmias on long-term prognosis and therapeutic decision-making.
TRIAL REGISTRATION
ISRCTN registry with study ID ISRCTN13744381 .
Identifiants
pubmed: 31030674
doi: 10.1186/s12968-019-0537-4
pii: 10.1186/s12968-019-0537-4
pmc: PMC6487526
doi:
Banques de données
ISRCTN
['ISRCTN13744381']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
25Commentaires et corrections
Type : ErratumIn
Références
Int J Cardiol. 2013 Sep 30;168(2):1147-53
pubmed: 23266299
Eur Radiol. 2015 Oct;25(10):3066-72
pubmed: 25791640
Circ Cardiovasc Imaging. 2016 Jul;9(7):
pubmed: 27363857
Eur Heart J. 2013 Aug;34(29):2281-329
pubmed: 23801822
Heart. 2009 Dec;95(23):1925-30
pubmed: 19710029
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Eur J Heart Fail. 2014 Nov;16(11):1160-7
pubmed: 25287281
J Cardiovasc Magn Reson. 2014 Jan 04;16:2
pubmed: 24387626
Neuromuscul Disord. 2004 Jan;14(1):33-8
pubmed: 14659410
J Cardiovasc Magn Reson. 2013 Dec 21;15:107
pubmed: 24359596
Pediatr Cardiol. 2014 Oct;35(7):1279-85
pubmed: 24830760
Neurology. 2015 Jul 28;85(4):357-64
pubmed: 26215877
Eur J Heart Fail. 2008 Sep;10(9):850-4
pubmed: 18692438
Circ Cardiovasc Imaging. 2017 Feb;10(2):
pubmed: 28213448
J Cardiovasc Magn Reson. 2013 Mar 27;15:27
pubmed: 23537111
Curr Cardiovasc Imaging Rep. 2010 Apr;3(2):83-91
pubmed: 20401158
J Cardiovasc Magn Reson. 2016 Oct 28;18(1):72
pubmed: 27788681
Biochim Biophys Acta. 2015 Apr;1852(4):607-14
pubmed: 24882751
J Cardiovasc Magn Reson. 2013 Oct 14;15:92
pubmed: 24124732
Heart Rhythm. 2012 Nov;9(11):1890-5
pubmed: 22760083
Neurotherapeutics. 2008 Oct;5(4):601-6
pubmed: 19019312
Eur J Radiol. 2015 Oct;84(10):1938-42
pubmed: 26210092
Cardiology. 2000;94(1):1-11
pubmed: 11111138
J Cardiovasc Magn Reson. 2013 May 01;15:35
pubmed: 23634753
Magn Reson Med. 2009 Jan;61(1):215-21
pubmed: 19097213
JACC Cardiovasc Imaging. 2013 Aug;6(8):889-98
pubmed: 23850250
Z Kardiol. 2005 May;94(5):348-54
pubmed: 15868364
Circulation. 2011 Nov 8;124(19):2145-54
pubmed: 22064958
Eur Heart J Cardiovasc Imaging. 2014 Sep;15(9):1004-12
pubmed: 24686257
Circulation. 2010 Feb 9;121(5):706-8
pubmed: 20142463
J Cardiovasc Magn Reson. 2014 Sep 25;16:81
pubmed: 25315351
MAGMA. 2000 Nov;11(1-2):82-3
pubmed: 11186999
Eur Heart J Cardiovasc Imaging. 2016 Mar;17(3):326-33
pubmed: 26113120
Circulation. 2013 Nov 19;128(21):2296-308
pubmed: 24036606
Neuromuscul Disord. 2009 Feb;19(2):140-2
pubmed: 19147353
Circulation. 2002 Jan 29;105(4):539-42
pubmed: 11815441
J Cardiovasc Magn Reson. 2008 Nov 04;10:50
pubmed: 18983659
Magn Reson Med. 2004 Jul;52(1):141-6
pubmed: 15236377
N Engl J Med. 2008 Jun 19;358(25):2688-97
pubmed: 18565861
Eur Neurol. 2006;56(1):1-5
pubmed: 16804309
Clin Res Cardiol. 2012 Apr;101(4):255-61
pubmed: 22143423